2026-09-05 · 2026-09 / week-1
Ionis loses pelacarsen, but cash and short crowding block a clean short
Ionis loses pelacarsen, but cash and short crowding block a clean short
Run timestamp: 2026-09-05 23:30 SGT Scope: U.S. market, short only Classification: No-trade screen, Reject for current execution Primary instrument: Ionis Pharmaceuticals common stock, Nasdaq, unlevered only if every short-execution gate later passes
Summary: Ionis's partner Novartis reported on September 4 that the Phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary cardiovascular endpoint. Ionis discovered the drug and licensed it to Novartis in 2019. The result removes a major late-stage royalty and pipeline option from the equity story, while Ionis still carries a large research budget, a royalty-sale liability, and a balance sheet that gives it time to fund the remaining portfolio.
The short setup is strongest as a repricing hypothesis, not as an order. The regular-session close was $58.09 on September 4. The latest extended-hours observation was $52.29 at 19:59 EDT, down 9.98% from the close. Extended-hours pricing is not a verified executable entry. At the August 14 settlement, public data showed 20.91 million shares short, 12.81% of public float, and 9.6 days to cover. That positioning can accelerate a second leg lower, but it also makes a squeeze a credible adverse path.
Using $52.29 only as a reference level, the modeled base case is $45.00 and the top case is $35.00. The bottom case is $64.00. The base decline is 13.94%, but the adverse rise is 22.39%, producing only 0.62:1 gross reward to adverse risk before borrow, spread, slippage, funding, and gap costs. The Desk therefore rejects the short under the 10/5 hurdle and keeps entry.price null and execution.can_execute false.
Opportunity Ranking
The search used mechanism-specific queries rather than a generic earnings query:
failed cardiovascular outcome trial royalty sale liability cash burn short float days to cover post-market gap
software platform growth deceleration beat raised guide investor day valuation reset September 2026
AI semiconductor revenue mix software miss record free cash flow short interest post-earnings gap
The current-week archive and September signal file were scanned before selection. Covered names and mechanisms, including the USAR resale shelf, SUNB rental-cycle reset, GWRE and EGAN expectation resets, NTSK cash-flow tension, and the existing retail and capital-return notes, were excluded. IONS is a new issuer-specific evidence boundary because the September 4 Form 8-K records a previously unresolved Phase 3 outcome. MDB and AVGO are fresh comparison candidates, not prior published thesis subjects in this run.
| Rank | Candidate | Direction | Mispricing | Evidence Freshness | Catalyst Window | Positioning | 10/5 Status | Tradeability | Main Rejection Risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Ionis Pharmaceuticals (IONS) | Short | The post-trial price may still carry value for a lost pelacarsen royalty and late-stage option, but cash, owned launches, and the remaining pipeline create a real floor | Sep. 4 Phase 3 result, Sep. 4 Form 8-K, June 30 10-Q, Sep. 4 close and extended-hours tape | Full HORIZON data, partner disposition, next pipeline and commercial updates | 12.81% of public float short and 9.6 DTC as of Aug. 14; live borrow and recall terms unknown | Reject | Nasdaq-listed and normally liquid, but the current reference is extended hours and the event can gap | Cash and launches can absorb the lost asset while crowded shorts cover |
| 2 | MongoDB (MDB) | Short | Atlas grew about 29% while total revenue grew 30%; the market may have expected acceleration, but the company raised FY27 guidance and reports 122% net ARR expansion | Sep. 1 results and 10-Q, Sep. 4 close and Sep. 29 Investor Day notice | Investor Day and next quarterly update | 3.62% of public float short and 1.7 DTC as of Aug. 14 | Reject | Large, but the stock already fell 13.54% on Sep. 2 and then rebounded after hours | $2.4B of cash, 30% growth, higher guide, and a strong operating countercase |
| 3 | Broadcom (AVGO) | Short | A high valuation and a software segment that can lag the AI narrative create a mix mismatch, but Q3 AI revenue grew 221% and Q4 guidance accelerated | Sep. 2 results, Sep. 4 close and extended-hours tape | Next quarterly report and AI demand conversion | 1.20% of public float short and 3.2 DTC as of Aug. 14 | Reject | Very liquid, but the current data still show record cash flow and strong demand | $13.7B Q3 free cash flow, $34.8B Q4 revenue guide, and $21.7B Q4 AI semiconductor guide |
Selected research subject: IONS.
Why this one now: It has the freshest binary fact, the clearest value bridge from a failed late-stage asset to a still-funded operating company, and the most important short-positioning tension. The failure is public, but the market has not yet seen the full data, partner decision, or post-event analyst and holder response.
What should surprise the reader: A failed cardiovascular outcome trial is not the same as a zero-value company. The balance sheet can fund time, while the same balance sheet and operating losses can make the lost royalty difficult to replace. The trade's immediate problem is not a lack of bearish evidence. It is that the adverse path is wider than the favorable path after a crowded event gap.
No-trade conclusion: IONS is the best current short research subject by catalyst urgency and evidence value, not the best executable short. All three candidates fail the 10/5 gate or lack the evidence needed to pass it.
Why This Is the Best Opportunity Right Now
The strongest counterparty case is simple. Ionis has $2.1 billion of cash, cash equivalents, and short-term investments as of June 30. It is commercializing TRYNGOLZA and DAWNZERA, has additional partnered programs, and says the full pelacarsen data will be presented at an upcoming medical congress. The September 4 release says the drug achieved substantial Lp(a) lowering and had an acceptable safety profile. A negative cardiovascular endpoint can still leave a commercially useful biomarker result, a subgroup question, or a partner decision that is less final than the first headline suggests. Ionis September 4 Form 8-K and pelacarsen release
That case does not erase the short. It defines the information boundary. The result is a direct failure on the endpoint that mattered for approval and commercialization in established cardiovascular disease. Ionis does not control the next development decision because Novartis licensed and funded pelacarsen's development. Ionis's June 10-Q shows $219.7 million of operating loss on $514.0 million of first-half revenue, while operating expenses reached $733.8 million. Commercial revenue was $226.4 million, including $134.3 million of royalty revenue and only $74.1 million of product sales. The company is moving toward independent commercialization, but the current revenue base does not make the lost option immaterial.
MDB has a cleaner tape but a stronger operating rebuttal. Its September 1 release reported $771.8 million of quarterly revenue, up 30%, Atlas growth of about 29%, and higher full-year guidance. Its 10-Q reports a 122% net ARR expansion rate and $2.4 billion of cash and short-term investments. AVGO is even harder to underwrite as a short after its September 2 report: $29.6 billion of Q3 revenue, $13.7 billion of free cash flow, $16.7 billion of AI semiconductor revenue, and a $34.8 billion Q4 revenue guide. IONS has the largest new fact and the largest positioning conflict, so it wins the research ranking while still failing the execution hurdle.
Why This Can Move More Than 5% Soon
The first move is already a 9.98% extended-hours decline from the regular close. The next move can exceed 5% because the first headline does not settle four linked questions:
- Whether the full HORIZON dataset shows a clinically meaningful subgroup or only confirms a biomarker effect without outcome benefit.
- Whether Novartis continues, limits, or ends the pelacarsen program and how Ionis describes the royalty and milestone consequences.
- Whether investors revalue Ionis's commercial products against the company's current expense base rather than against a multi-asset pipeline narrative.
- Whether the 12.81% reported short float becomes incremental selling pressure or a forced-covering bid after the opening print.
The first three are fundamental catalysts. The fourth is market structure. It can amplify either direction and is why a post-event short cannot be protected by an assumed 5% stop or by a reference price observed in extended hours.
10/5 Asymmetry Gate
The map uses the latest extended-hours observation as a reference, not as an entry. For a short, the top case is the lowest price and the bottom case is the highest price.
| Measure | Reference-only result | Interpretation |
|---|---|---|
| Reference price | $52.29 | StockAnalysis observation at 2026-09-04 19:59 EDT; extended-hours and non-executable |
| Top-case target | $35.00 | 33.09% favorable underlying decline |
| Base-case target | $45.00 | 13.94% favorable underlying decline |
| Bottom-case target | $64.00 | 22.39% adverse underlying rise |
| Gross reward to adverse risk | 0.62:1 | ($52.29 - $45.00) / ($64.00 - $52.29), below the required 2:1 |
| Probability-weighted target | $46.75 | 30% top, 45% base, 25% bottom; price-only estimate |
| Price-only expected decline | 10.60% | ($52.29 - $46.75) / $52.29 before costs |
| Measurement basis | Reference-only | entry.price is null |
| Status | Reject / no-trade screen | Credible adverse path and missing execution gates are decisive |
The base case clears the favorable 10% screen, and the probability-weighted price-only result is positive for a short. That is not enough. The adverse path is more than four times the permitted 5% boundary, and the gross ratio is below 2:1 before the borrow fee, spread, slippage, funding, recall, buy-in, and event-gap costs. The numerical map is a transparent underwriting estimate, not an observed frequency or a promise.
What Should Surprise the Reader
- The failed trial does not directly remove all Ionis revenue. The June 10-Q shows $226.4 million of first-half commercial revenue, but most of that figure is royalty revenue and the company remains loss-making at the operating level.
- The cash balance is a floor against immediate financing stress, not a valuation floor. At June 30, Ionis held $2.0546 billion in cash and short-term investments against $1.3226 billion of convertible notes, a $562.6 million royalty-sale liability, and $262.5 million of long-term lease liabilities.
- The royalty-sale liability matters. Ionis received $500 million upfront for a minority interest in future SPINRAZA and pelacarsen royalties. The liability is carried at $575.5 million net at June 30 and accrues interest at an estimated 12.0% effective rate. A failed pelacarsen outcome changes the economic context, but the accounting balance does not automatically equal a cash refund or an immediate write-off.
- A high short balance is both fuel and risk. The August 14 data predate the event. They say something about the crowded starting state, not about today's borrow availability or the direction of the next trade.
The Setup
Ionis discovered pelacarsen and conducted its early development. Novartis exercised an option in February 2019 to license development and commercialization rights. The September 4 Form 8-K records that the Lp(a)HORIZON Phase 3 trial did not meet its primary endpoint of reducing a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared with placebo. The study enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease. Ionis Form 8-K, Exhibit 99.1
The release also states that pelacarsen substantially lowered Lp(a), had an acceptable safety profile, and will have its full data presented at an upcoming medical congress. Those facts prevent a responsible analyst from treating the program as legally or economically extinguished. They do establish that the pivotal outcome evidence failed the endpoint the market needed for a straightforward approval case.
The balance sheet shows why the short is a time-value argument rather than a solvency call. Ionis had $350.1 million of cash and $1.7045 billion of short-term investments at June 30. It owed $770 million of 0% convertible notes due 2030 and $600 million of 1.75% convertible notes due 2028 at principal value. It also carries the royalty-sale liability and long-term leases. Six-month operating expenses were $733.8 million and the operating loss was $219.7 million. The company says its cash, investments, and plans for future cash are sufficient for planned operations, but it also warns that failure to commercialize medicines or license assets could require additional funding.
The core commercial base is growing but small relative to the spend. TRYNGOLZA sales were $31.7 million in the first half and DAWNZERA sales were $42.4 million. Total royalty revenue was $134.3 million. The June 10-Q says commercial revenue increased 27% year over year in the first half, primarily due to DAWNZERA product sales. Growth is real. The question is whether it can replace the development and commercial option value that the pelacarsen result just impaired.
The Market Price
| Field | Observation | Timestamp or date | Source and limitation |
|---|---|---|---|
| Regular-session close | $58.09 | 2026-09-04 16:00 EDT | StockAnalysis IONS history; completed market print |
| Regular-session change | -$0.04, -0.07% | Same close | Same source; the trial result was disclosed after the close |
| Regular-session range and volume | $57.78 to $58.96; 2,208,001 shares | Same session | Same source; does not establish future depth or borrow |
| Extended-hours observation | $52.29, -9.98% from close | 2026-09-04 19:59 EDT | StockAnalysis IONS history; extended-hours and non-executable |
| Extended-hours range | $50.71 to $58.16 | Latest extended-hours session | Public IONS after-hours data; venue-specific context, not a consolidated book |
| Shares outstanding | 166,184,322 | 2026-07-23, latest 10-Q cover date | Ionis Q2 Form 10-Q; later changes are unknown |
| Implied equity value at reference | About $8.69B | $52.29 multiplied by 166.184M shares | Derived reference arithmetic; not a provider market-cap field and not a valuation floor |
The event was released after the September 4 regular session. The $52.29 figure is the most relevant current reference available in the research run, but it is a thin, extended-hours observation. A Monday regular-session open can gap above or below it. No top-of-book, depth, venue-quality, volume-quality, or realistic exit audit is available, so no entry price is authorized.
The Mispricing
Fact: Novartis and Ionis reported a Phase 3 failure on the primary cardiovascular endpoint, while Lp(a) lowering and safety remained acceptable. The full dataset is still pending. Ionis Form 8-K
Fact: Ionis's first-half operating loss was $219.7 million on $514.0 million of revenue. Commercial revenue was $226.4 million, product sales were $74.1 million, and royalty revenue was $134.3 million. Ionis Q2 Form 10-Q
Fact: The latest extended-hours reference is $52.29, down 9.98% from the regular close. StockAnalysis IONS history
Inference: The first reaction may not yet reflect a complete reset of the lost pelacarsen royalty and late-stage option, because the partner's next decision, the full dataset, and the market's replacement value for the remaining pipeline are not yet visible.
Reasonable assumption: A partial reset toward the value of the owned commercial products and the remaining pipeline can take the stock toward the $45 base case if the full data do not produce a credible subgroup and if new launch revenue does not offset the current cost base.
Unknown: The economic terms of any post-result partner decision, the exact future royalty impact, the full event rates and subgroup data, the current cash burn after the result, the next quarter's commercial trajectory, and whether the market already incorporated the result in other venues before the published after-hours print.
The disagreement is therefore narrower than “the drug failed, so the stock is worth zero.” The short case is that a multi-billion-dollar equity value still gives significant credit to a late-stage asset that failed its pivotal outcome test, while the replacement assets require time and cash to prove commercial scale. The countercase is that cash, owned launches, and a diversified pipeline make the lost asset a painful haircut rather than a broken company.
The Positioning
MarketBeat reports 20,909,181 shares short as of the August 14 settlement, equal to 12.81% of public float and 9.6 average days to cover. Short interest fell 2.59% from the prior report. These figures are stale relative to the September 4 event and use a vendor-defined public float. They are useful as a crowding indicator, not as current execution data. MarketBeat IONS short interest
The positioning tension is unusually two-sided:
- A failed pivotal endpoint can trigger additional fundamental selling, analyst-target resets, and fund de-risking.
- A 12.81% short float and 9.6 DTC can create forced buying if the full dataset is less negative, if Novartis preserves an option, or if launch data are better than feared.
- A post-event short may inherit borrow recalls, rising fees, buy-in risk, and hard-to-exit gaps even if the thesis is directionally correct.
Current positioning score: 4/5 for tension, 2/5 for completeness. The public short balance is non-trivial, but live securities-lending availability, broker-level locate, fee, utilization, recall and buy-in terms, options dealer exposure, holder concentration, and post-event fund flows are not verified. The missing data are decisive for a short expression.
The Catalyst
| Step | State | Timing | Observable test | Failure mode |
|---|---|---|---|---|
| Lp(a)HORIZON primary result | Completed | September 4, 2026 | Confirm the failed endpoint, event population, and safety language in the Form 8-K | A later correction or fuller result materially changes the first read |
| Full HORIZON data | Announced, date not stated | Upcoming medical congress | Read event counts, effect estimates, confidence intervals, subgroups, and safety; compare the endpoint to the release | A clinically meaningful subgroup or a more favorable effect profile restores option value |
| Novartis program decision | Unknown | After full data and partner review | Verify continuation, termination, or changed development and commercialization terms | The partner preserves or increases the asset's value |
| Owned-product conversion | In progress | Next quarterly report and commercial updates | Reconcile TRYNGOLZA and DAWNZERA sales, gross-to-net, launch spend, persistence, and payer access | Commercial growth replaces the lost option value faster than expected |
| Cash and expense bridge | In progress | Next quarterly filing | Separate cash, investments, operating cash use, R&D, SG&A, debt service, royalty payments, and lease commitments | Cash burn falls or partner funding increases, reducing financing risk |
| Positioning response | Unknown | First regular session after the event | Verify opening price, close, volume, spread, depth, borrow, and failed-to-deliver or buy-in signals where available | Covering or a thin book produces a squeeze before fundamental repricing |
The cheapest falsification sequence is not a chart level. It is: read the full dataset when released, verify Novartis's actual program decision, then reconcile the next cash and commercial filing. If those three observations show a credible outcome subgroup, a funded partner path, and improving product economics, the short thesis is wrong. If they show no outcome benefit, program retrenchment, and persistent burn, the replacement-value disagreement strengthens.
The Payoff
The scenario map uses one horizon: from the first regular session after the September 4 disclosure through the first full-data and next-quarter evidence window. Because the medical-congress date and partner decision are not fixed, the horizon is event-defined rather than a calendar promise.
| Scenario | Probability | Target / Level | Return / Payoff | Horizon | Conditions | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 30% | $35.00 | 33.09% favorable short move from reference | Event-defined, through full data and next filing | No meaningful outcome subgroup, Novartis retrenches, owned-product revenue does not offset the cost base, and the market removes more pipeline value | Medium |
| Base Case | 45% | $45.00 | 13.94% favorable short move from reference | Same | The failed endpoint is confirmed, the program's value is reduced, launches grow but remain too small for the current spend, and cash delays rather than prevents a reset | Medium |
| Bottom Case | 25% | $64.00 | 22.39% adverse rise from reference | Same | Full data are less negative, Novartis retains a funded option, owned launches beat expectations, or crowded shorts cover into a thin regular-session book | Medium |
| Invalidation | n/a | Above $64 with favorable full-data and cash evidence, or a verified partner-led recovery case | n/a | Same | Replacement value is demonstrated rather than narrated | High / Medium |
Probability-weighted expected value: 0.30 x $35.00 + 0.45 x $45.00 + 0.25 x $64.00 = $46.75 reference-only target, or a 10.60% price-only expected decline before costs.
Current market level and timestamp: $52.29 extended hours at 2026-09-04 19:59 EDT, equivalent to 2026-09-05 07:59 SGT. The publication timestamp is 2026-09-05 23:30 SGT.
Primary instrument: IONS common stock, unlevered only after every short-execution gate passes.
10/5 favorable base move: 13.94% from the reference-only level.
10/5 credible adverse move: 22.39% from the reference-only level.
10/5 measurement basis: Reference-only, not verified executable entry.
10/5 status: Reject.
Confidence: Medium on the event fact and balance-sheet bridge; low on the target map because full data, partner economics, current borrow, and regular-session price acceptance are unresolved.
The Kill Shot
The mature counterparty says the market is overreacting to a single endpoint. Pelacarsen lowered Lp(a), was safe, and could still inform a narrower indication or future preventive study. Ionis is not a one-asset company. It has cash, two independent commercial launches, partnered medicines, and a pipeline that can generate milestones and royalties. The stock can rerate on any evidence that the new commercial products have better persistence or reimbursement than the market expects.
That argument defeats a zero-value short, not the narrower repricing thesis. The load-bearing assumption is that the remaining assets cannot replace the lost pelacarsen option quickly enough to justify the current equity value. If that assumption is wrong, the short loses. The evidence that would break it is a credible full-data subgroup, an explicit Novartis continuation with funded milestones, accelerating TRYNGOLZA and DAWNZERA sales, or a material reduction in operating cash use.
The trade can also lose while the thesis is directionally right. A gap above the reference can force a buy-in. A recall can remove the locate. A wide opening spread can make the modeled $45 target irrelevant. The result can be delayed in the tape while the company retains enough cash to fund several quarters of development. These are not footnotes. They are the reason the Desk rejects the expression.
What Could Go Wrong
Trial interpretation risk: The headline omits the full event-rate and subgroup detail. A clinically meaningful subgroup or favorable safety and biomarker combination could preserve value.
Partner risk: Novartis funded development and holds the commercial rights. It may continue the program, redirect it, or provide information that changes the value assigned by the market.
Cash-floor risk: $2.1 billion of cash and short-term investments can fund time and reduce near-term financing pressure. Treating the post-event equity as a simple cash-minus-debt residual ignores R&D, SG&A, leases, royalty payments, manufacturing, and launch spending.
Pipeline risk: Ionis has multiple partnered and wholly owned programs. A positive regulatory or clinical update can create a new option before pelacarsen's value is fully written down.
Crowded-short risk: 12.81% of public float and 9.6 DTC are pre-event observations. Covering, borrow recalls, or a favorable data leak can produce a rapid squeeze.
Gap and halt risk: A biotech can open far from any modeled level after a trial update. A halt or an uneven reopening can bypass any assumed stop distance.
Liquidity risk: The regular session traded 2.21 million shares, but current depth, spread, venue quality, volume quality, and realistic exit liquidity are unverified. Extended-hours range is not a consolidated executable book.
Carrying-cost risk: Borrow fee, utilization, recall, buy-in terms, funding, and settlement status are unknown. The signal cannot authorize a short without them.
What Would Prove This Wrong
The thesis is invalidated by evidence, not by a single bounce:
- Full HORIZON data show a robust clinically meaningful subgroup or an outcome profile that supports a credible development path.
- Novartis explicitly continues pelacarsen with funded development and a clear economic path for Ionis.
- TRYNGOLZA and DAWNZERA sales accelerate enough to narrow the gap between commercial revenue and operating expense, with gross-to-net and launch costs disclosed.
- Ionis's next cash-flow statement shows materially lower burn without new dilution or a new royalty sale.
- A fresh regular-session market audit shows stable price acceptance, verified borrow, and a squeeze-adjusted risk profile that is no longer adverse beyond 5%.
Until those observations arrive, the result supports further research but not an executable short.
Risk Audit
| Risk | Evidence | Control |
|---|---|---|
| Event gap | $52.29 was an extended-hours reference after a failed Phase 3 result | Keep entry.price null until a regular-session quote and exit path are verified; do not use a fixed stop as protection |
| Borrow and recall | Public short interest is high; live locate and loan terms are missing | Require account-level locate, fee, utilization, recall, buy-in, and settlement evidence; otherwise do not trade |
| Squeeze | 12.81% public-float short and 9.6 DTC as of Aug. 14 | Model the $64 adverse case; reject if favorable reward to adverse risk remains below 2:1 |
| Fundamental floor | $2.1B cash and short-term investments; owned products and partnered pipeline | Reconcile cash, debt, royalty liability, leases, burn, product sales, and partner funding before revising targets |
| Data ambiguity | Full trial data and partner decision are pending | Use the full-data and partner-decision sequence as the falsification test |
| Liquidity and exit | Regular-session volume is not a depth or fill guarantee | Verify bid, ask, spread, depth, venue, volume quality, and realistic cover liquidity |
| Instrument risk | No live option chain and maximum-loss analysis were verified | Common stock only in the research state; no options, leverage, margin, market orders, or price-floor claims |
Best Trade Strategy
Current decision: No executable trade. IONS is a Reject under the short 10/5 policy and remains a research-only screen.
Primary expression: Unlevered IONS common stock only after a fresh regular-session quote, broker-level locate, current borrow fee, utilization, recall and buy-in terms, acceptable bid and ask, spread, depth, venue quality, volume quality, settlement, and realistic exit liquidity are verified. The full HORIZON data and the partner's decision must also be available for a responsible re-underwrite. These are research conditions, not an order.
Reference-only levels: Top $35.00, base $45.00, bottom $64.00. The invalidation state is a verified replacement-value recovery, not a mechanical stop.
Horizon: From the first regular session after the result through the full-data and next-quarter evidence window. The medical-congress date and partner decision are not verified, so no calendar deadline is promised.
Do not trade when: the only quote is extended hours; the opening book gaps above the $64 stress level; the full dataset is unavailable; Novartis continuation is unpriced or unclear; locate, borrow, recall, buy-in, spread, depth, venue, volume quality, settlement, or exit liquidity is unknown; or the remaining pipeline produces a favorable clinical or regulatory surprise.
Alternative: A defined-loss put or put spread could limit a squeeze, but no live option chain, spread, implied volatility, expiry, assignment terms, or maximum-loss audit was verified. It is not an approved substitute.
Sources
- Ionis September 4 Form 8-K and Exhibit 99.1 - Phase 3 Lp(a)HORIZON endpoint result, safety, full-data notice, licensing history, and company response, September 4, 2026.
- Ionis Q2 2026 Form 10-Q - cash, investments, debt, royalty-sale liability, leases, revenue mix, expenses, operating loss, products, and risk disclosures, filed July 29, 2026.
- Ionis Q2 2026 results release - commercial revenue growth, cash context, product launches, and pipeline milestones, July 29, 2026.
- Ionis regular-session price history - September 4 close, range, volume, and extended-hours observation.
- Ionis after-hours market data - venue-specific extended-hours range and last observation, September 4, 2026.
- Ionis short interest - public short interest, float percentage, days to cover, and settlement history through August 14, 2026.
- MongoDB Q2 FY27 results - candidate comparison: revenue, Atlas growth, guidance, and profitability, September 1, 2026.
- MongoDB Q2 FY27 Form 10-Q - candidate comparison: cash, net ARR expansion, customer base, and revenue mix, filed September 1, 2026.
- MongoDB price history - candidate comparison: September 2 to 4 price reaction and volume.
- MongoDB short interest - candidate comparison: public short interest and days to cover as of August 14, 2026.
- MongoDB events - candidate comparison: September 29 Investor Day, accessed September 5, 2026.
- Broadcom Q3 FY26 results - candidate comparison: AI revenue, consolidated guidance, margin, and free cash flow, September 2, 2026.
- Broadcom price history - candidate comparison: September 4 close, volume, and extended-hours observation.
- Broadcom short interest - candidate comparison: public short interest and days to cover as of August 14, 2026.
Research Quality Scorecard
| Criterion | Score | Evidence and deduction |
|---|---|---|
| Market disagreement | 4/5 | A pivotal endpoint failed while the equity still carries replacement-value expectations; the cash floor prevents a stronger score |
| Evidence base | 5/5 | Fresh Form 8-K and primary 10-Q provide direct event, balance-sheet, revenue, and cost evidence |
| Positioning and flows | 3/5 | Short float and DTC are useful, but stale; locate, borrow, holder, dealer, and post-event flow data are missing |
| Catalyst path | 4/5 | Full data, partner decision, commercial conversion, and next filing form an observable sequence; dates are incomplete |
| Payoff architecture | 3/5 | Scenario targets and probabilities are explicit, but the adverse path defeats the hurdle |
| Invalidation discipline | 4/5 | Full-data, partner, commercial, cash, and execution invalidators are monitorable |
| Differentiated insight | 4/5 | The key disagreement is replacement value versus time funded by cash, not a zero-value trial-failure story |
| Client value | 5/5 | The screen identifies why a compelling event does not justify chasing an unverified and crowded short |
Total: 32/40. The score supports a substantive no-trade screen. It does not override the failed 10/5 gate, missing execution data, or the 22.39% credible adverse path.
Bottom Line
Ionis's failed pelacarsen endpoint is a real negative fact with a clear valuation consequence: one of the company's largest late-stage options must be re-underwritten. The remaining company has cash, commercial launches, and a pipeline, so the correct bear case is a slower replacement of value against a large expense base, not a claim that the equity is worthless.
IONS is the best current U.S. short research subject in this screen because the catalyst is fresh and the positioning tension is visible. It is not a qualified trade. The reference price is extended hours, the next data are binary, borrow and exit conditions are unverified, and the modeled adverse squeeze is more than four times the allowed 5% path. The Desk's decision is Reject and wait for evidence, not chase the gap.
AI Illustration Prompt
Create a restrained editorial illustration for The Mispricing Desk: a scientific trial report stamped “endpoint missed” lies on a dark slate laboratory desk beside a half-filled cash ledger, two medicine vials labeled “owned launches,” and a narrow red ticker tape falling from $58.09 to $52.29 after hours. In the background, a crowded doorway of small black silhouettes represents 12.81% short float and 9.6 days to cover, with one bright exit door showing a squeeze path upward. Use graphite, muted cobalt, bone paper, and one controlled red accent; sharp financial-document textures, no logos, no trading instructions, no decorative candlestick chart. Leave generous negative space for a headline and include a subtle readable “The Mispricing Desk” watermark in the lower-right corner.